AbbVie

Social media sentiment, last 30 days

Average tone of posts mentioning ABBV, from −1 (all negative) to +1 (all positive). Latest day: +0.00 across 29 mentions.

• Press releaseOct 20, 7:55 AM ETPRNewswire

  AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community

• Press releaseOct 19, 4:00 AM ETPRNewswire

  AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease

• Press releaseOct 18, 6:10 PM ETPRNewswire

  AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

• Press releaseOct 18, 6:09 PM ETPRNewswire

  /C O R R E C T I O N - AbbVie/

• Press releaseOct 17, 2:00 AM ETPRNewswire

  SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

• NewsOct 14, 11:39 AM ETPiero Cingari

  Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today

• Press releaseOct 13, 3:15 PM ETPRNewswire

  AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease

• NewsOct 13, 1:20 PM ETVandana Singh

  Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?

• NewsOct 13, 7:28 AM ETAvi Kapoor

  Netflix, DocuSign And A Health Care Stock On CNBC’s ‘Final Trades’

• Press releaseOct 11, 1:00 PM ETPRNewswire

  New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

• NewsOct 10, 1:54 AM ETTanya Rawat

  John Moolenaar Urges Defense Department to Add 120 Chinese Schools and Tech Labs to US Research Funding Watchlist

• NewsOct 7, 10:52 PM ETMohd Haider

  Why is AbbVie (ABBV) Stock Trending After Hours?

• Press releaseOct 7, 8:30 AM ETPRNewswire

  AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC

• Press releaseOct 5, 2:54 PM ETPRNewswire

  AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

• Press releaseOct 5, 2:50 PM ETBusiness Wire

  Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

• Press releaseOct 5, 2:49 PM ETGlobe Newswire

  Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

• Press releaseOct 1, 10:00 AM ETPRNewswire

  AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo

• Press releaseOct 1, 8:00 AM ETPRNewswire

  AbbVie to Host Third-Quarter 2026 Earnings Conference Call

• NewsSep 30, 10:49 AM ETVandana Singh

  AbbVie Reveals Positive Data for Eczema and Weight Loss Candidates

• NewsSep 30, 8:07 AM ETAvi Kapoor

  Eaton, AMD, SpaceX And A Health Care Stock: CNBC’s ‘Final Trades’

• Press releaseSep 30, 5:45 AM ETPRNewswire

  AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026

• Press releaseSep 30, 1:30 AM ETPRNewswire

  AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026

• Press releaseSep 30, 1:00 AM ETPRNewswire

  AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress

• NewsSep 29, 10:41 AM ETAvi Kapoor

  UnitedHealth, AbbVie And A Health Care Stock On CNBC’s ‘Final Trades’

• Press releaseSep 29, 9:00 AM ETPRNewswire

  AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

• NewsSep 28, 1:38 PM ETVandana Singh

  AbbVie’s New Parkinson’s Pill Could Become a Billion-Dollar Drug, Analyst Says

• Press releaseSep 28, 8:00 AM ETPRNewswire

  U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

• NewsSep 25, 1:35 PM ET

  10 Health Care Stocks With Whale Alerts In Today’s Session

• NewsSep 24, 1:35 PM ET

  10 Health Care Stocks Whale Activity In Today’s Session

• NewsSep 22, 4:10 PM ETChris Katje

  Congressman with $11.5 Million in Trades Keeps Selling Stocks: Here’s the Latest Moves

• Press releaseSep 22, 8:00 AM ETPRNewswire

  Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach

• Press releaseSep 22, 2:00 AM ETPRNewswire

  AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis

• NewsSep 8, 11:27 AM ETChandrima Sanyal

  Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back

• NewsSep 3, 8:46 AM ET

  AbbVie Anticipates Apogee Acquisition To Negatively Impact Adj Diluted EPS By $0.14 This Year, $0.46 In 2027, Accretion Beginning In 2032

• Press releaseSep 3, 8:34 AM ETPRNewswire

  AbbVie Completes Acquisition of Apogee Therapeutics

• Press releaseAug 18, 12:57 PM ETGlobe Newswire

  A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.

• Press releaseAug 4, 9:05 AM ETGlobe Newswire

  Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One

• NewsAug 3, 1:13 PM ETVandana Singh

  AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

• NewsFeb 11, 9:00 AM ET

  P/E Ratio Insights for AbbVie

• NewsJan 6, 7:29 AM ETAvi Kapoor

  Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

• NewsDec 10, 7:26 AM ETAvi Kapoor

  This AbbVie Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

• NewsOct 14, 8:17 AM ETAvi Kapoor

  Amazon, AbbVie, Datadog And A Financial Stock: CNBC's 'Final Trades'

• NewsAug 22, 11:10 AM ETHenry Khederian

  Tesla's Quality Score Tumbles, While Taiwan Semiconductor's Growth Rating Soars

• NewsAug 1, 12:33 PM ETNic Chahine

  5 Dividend Stocks With Solid Returns And More Growth Ahead

• NewsJul 11, 7:53 AM ETAvi Kapoor

  Boeing, Joby Aviation, Oracle And A Health Care Stock: CNBC's 'Final Trades'

• NewsMay 15, 1:08 AM ETShomik Sen Bhattacharjee

  Jim Cramer Says Even 'Safety' Stocks Look Risky, Warns Of 'Wild Card' In Washington And Rising Treasury Yields As Reasons To Stay Away From Sure Bets

• NewsMay 13, 3:00 PM ET

  A Look Into AbbVie Inc's Price Over Earnings

• NewsDec 23, 3:53 PM ETErica Kollmann

  Schwab US Dividend Equity ETF Reverses In December: What's Going On?